Sitryx to Participate in Upcoming Investor Conferences
Oxford, UK and Boston, MA – 2 September 2026 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
Oxford, UK and Boston, MA – 2 September 2026 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announced that management will be participating in the following upcoming investor conferences:
Wells Fargo 21st Annual Healthcare Conference
Date: Tuesday, 8 September – Thursday, 10 September 2026
Location: Boston, MA, US
Format: Presentation and 1×1 meetings
Presentation date and time: 8 September, 12.45 ET
Webcast access here
Morgan Stanley 24th Annual Global Healthcare Conference
Date: Monday, 14 September – Wednesday, 16 September 2026
Location: New York, NY, US
Format: Presentation and 1×1 meetings
Presentation date and time: 14 September, 13.05 ET
Webcast access here
Stifel Virtual Immunology and Inflammation Forum
Date: Wednesday, 23 September 2026
Location: Virtual
Format: Presentation and 1×1 meetings
Needham Private Company Conference – Biotech and MedTech
Date: Tuesday, 13 October – Wednesday, 14 October 2026
Location: Virtual
Format: 1×1 meetings
Interested investors should contact their bank representatives to schedule meetings during the events. Webcasts of presentations will be accessible via the Events page of the Sitryx website.
Ends
For more information about Sitryx please contact:
ICR Healthcare
Mary-Jane Elliott, David Daley, Evi Useh
+44 (0)20 3709 5700
Sitryx@icrhealthcare.com
About Sitryx
Sitryx is a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease. The Company has a broad pipeline of novel small molecule candidates targeting major autoimmune indications with high unmet need. Its lead candidate, SYX-5219, is a potentially first-in-class PKM2 modulator in development for atopic dermatitis as a once-daily oral therapy with future development potential across multiple autoimmune diseases.
Established with seed funding from SV Health Investors, Sitryx has an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Oxford Science Enterprises, Longwood Fund, Eli Lilly and Company, and GSK.
Sitryx is headquartered in Oxford, UK with additional presence in Boston, MA. For more information, please visit www.sitryx.com.
